Founded in 2014, Yirdoc is a specialized developer of customized mesh nebulizer technologies for advanced inhalation drug delivery. Over the past decade, the company has focused on one clear mission: helping pharmaceutical partners improve inhalation therapy through precision-engineered aerosol delivery systems. Rather than treating the device as a standard accessory, Yirdoc views aerosol performance as an essential part of drug development strategy. Yirdoc’s core strength lies in customized mesh design for inhalation delivery. The company works to align nebulizer performance with the needs of specific formulations and therapeutic goals, supporting more effective and targeted drug delivery to the respiratory tract. This approach is especially relevant as inhalation therapies continue to expand beyond conventional respiratory products and into more complex and high-value treatment areas. In this context, device performance is no longer just a technical specification. It directly influences delivery efficiency, consistency, patient usability, and the overall development pathway of inhaled products. The company operates through a strategically structured platform that supports innovation, manufacturing, and global collaboration. Yirdoc’s R&D Center is located in Qingdao, where its engineering and development teams focus on advancing mesh nebulizer technology and improving aerosol delivery performance. Its manufacturing plant in Changsha provides the production capability needed to scale customized solutions with quality and reliability. To strengthen communication and cooperation with international partners, Yirdoc also maintains a branch office in Boston, allowing the company to stay close to the needs of the US and global pharmaceutical markets. Today, Yirdoc is supported by a team of approximately 70 engineers and specialists and generates annual revenue of around USD 15 million. This combination of technical talent, operational capability, and commercial growth reflects the company’s steady development as a focused player in inhalation drug delivery. Yirdoc is not positioned as a general device supplier. Instead, it aims to be a professional partner for pharmaceutical companies seeking tailored nebulization solutions and stronger integration between formulation and delivery technology. At ATS, Yirdoc is pleased to present its vision for the future of inhalation therapy: a future in which device design contributes directly to therapeutic success. By combining specialized mesh nebulizer technology, application-focused engineering, and a commitment to pharmaceutical innovation, Yirdoc supports the development of smarter and more effective inhalation solutions. With a foundation built on engineering expertise and a long-term focus on customized inhalation delivery, Yirdoc is committed to empowering pharmaceutical innovation through the subtle power of mesh technology.
UF Health Shands
The University of Florida’s Pulmonary, Critical Care, Lung Transplant, and Thoracic Programs form one of the nation’s premier destinations for complex lung and airway disease. As a high-volume referral center, UF provides advanced care for patients with the most challenging medical and surgical needs, including highly HLA-sensitized individuals, those requiring ECMO support, patients with multi-organ dysfunction, and adults or children needing lung or multi-organ transplantation. UF’s Pulmonary Vascular Disease Center and Rare Lung Disease Program delivers nationally recognized expertise across pulmonary arterial hypertension, hereditary hemorrhagic telangiectasia, lymphangioleiomyomatosis, and pulmonary alveolar proteinosis, each supported by accreditation as a Center of Excellence from leading national foundations. Integrated closely with thoracic surgery and cutting-edge research teams, these programs collectively drive innovation in diagnosis, therapeutics, and multidisciplinary care, establishing UF as a leading hub for advanced lung disease and transformative respiratory medicine.
Rhythm Healthcare
Rhythm Healthcare is a market leader in respiratory and durable medical equipment (DME), recognized for its portfolio of best-in-class, reliable oxygen concentrators. Focused on continuous innovation, engineering excellence, and unparalleled customer support, Rhythm Healthcare is committed to empowering patients with mobility and independence while offering industry-leading products and the robust Rhythm Resolve brand-new replacement warranty program to its HME provider partners.
Pulmonary Hypertension Association
Headquartered in Washington, D.C., the Pulmonary Hypertension Association is the oldest and largest nonprofit patient association dedicated to the pulmonary hypertension community. PHA’s mission is to extend and improve the lives of those affected by PH. Through support, advocacy and awareness, education, quality care and research programs, PHA empowers patients, caregivers, families, health care professionals and researchers worldwide. Our 2026 PHA International PH Conference and Scientific Sessions will take place on June 11-14, 2026 in Dallas.